TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
Brief Summary: This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.


Options:
A: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: placebo needle; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo needle | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: placebo needle; Assigned to Arm(s): placebo needle
B: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: combined sono-electro-magnetic therapy (Sonodyn Medico Star) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo therapy (Placebo Sonodyn Medico Star) | Intervention Type: DEVICE; Name: combined sono-electro-magnetic therapy (Sonodyn Medico Star); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: placebo therapy (Placebo Sonodyn Medico Star); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
Brief Summary: This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.


Options:
A: N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Alfuzosin; Type: EXPERIMENTAL; Interventions: Drug: Alfuzosin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alfuzosin; Assigned to Arm(s): Alfuzosin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
Brief Summary: This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.


Options:
A: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
B: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: placebo needle; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo needle | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: placebo needle; Assigned to Arm(s): placebo needle
C: Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A
D: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression
Brief Summary: This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.


Options:
A: Arm Label: olanzapine/sertraline combination; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Sertraline | Arm Label: olanzapine plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olanzapine, Other: placebo | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): olanzapine plus placebo, olanzapine/sertraline combination | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): olanzapine/sertraline combination | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): olanzapine plus placebo
B: Arm Label: mifepristone 300 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: mifepristone matched placebo | Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone 600 mg | Arm Label: mifepristone 1200 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone 1200 mg | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): mifepristone 300 mg | Intervention Type: DRUG; Name: mifepristone matched placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: mifepristone 600 mg; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: mifepristone 1200 mg; Assigned to Arm(s): mifepristone 1200 mg
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matching placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clozapine Treatment of Schizophrenic Patients
Brief Summary: This study will determine whether adding the drug risperidone (Risperdal®) is more effective than placebo in treating schizophrenic patients who are taking the drug clozapine.


Options:
A: Arm Label: Cariprazine 3mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 6mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Aripiprazole 10mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 3mg, Cariprazine 6mg | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol
C: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperdal | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Risperdal; Assigned to Arm(s): Active
D: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #468 Phase I - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease
Brief Summary: The goals of this study are to determine if simultaneous bilateral subthalamic nucleus stimulation or simultaneous bilateral globus pallidus stimulation is more effective in reducing symptoms of Parkinson's disease, and if deep brain stimulation or best medical therapy is more effective in improving Parkinson's disease symptoms


Options:
A: Intervention Type: DEVICE; Name: Deep brain stimulation of the internal globus pallidus; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Deep brain stimulation (DBS) | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Deep brain stimulation (DBS) | Intervention Type: DEVICE; Name: Deep brain stimulation (DBS); Assigned to Arm(s): 1, 2
C: Intervention Type: DEVICE; Name: Deep brain stimulation; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Bilateral Deep Brain Stimulation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: best medical therapy | Intervention Type: DEVICE; Name: Bilateral Deep Brain Stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: best medical therapy; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relaxation Response, Somatic Style and Rheumatoid Arthritis
Brief Summary: This study will evaluate the relative effectiveness of Relaxation Response (RR) training for the treatment of rheumatoid arthritis (RA). The study will compare RR training to RR training with cognitive behavioral therapy and to a standard RA education program.


Options:
A: Arm Label: Pain Ed; Type: EXPERIMENTAL; Interventions: Behavioral: Pain Ed, Other: Usual Care | Arm Label: CBT for Pain; Type: EXPERIMENTAL; Interventions: Behavioral: CBT for Pain, Other: Usual Care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Pain Ed; Assigned to Arm(s): Pain Ed | Intervention Type: BEHAVIORAL; Name: CBT for Pain; Assigned to Arm(s): CBT for Pain | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): CBT for Pain, Pain Ed, Usual Care
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducative program in fibromyalgic patients | Intervention Type: BEHAVIORAL; Name: Psychoeducative program in fibromyalgic patients; Assigned to Arm(s): 1
C: Arm Label: CBT plus relaxation response; Type: EXPERIMENTAL; Interventions: Behavioral: Relaxation response and cognitive behavioral therapy | Arm Label: Relaxation Response; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relaxation response | Arm Label: Education; Type: PLACEBO_COMPARATOR; Interventions: Other: RA education | Intervention Type: BEHAVIORAL; Name: Relaxation response and cognitive behavioral therapy; Assigned to Arm(s): CBT plus relaxation response | Intervention Type: BEHAVIORAL; Name: Relaxation response; Assigned to Arm(s): Relaxation Response | Intervention Type: OTHER; Name: RA education; Assigned to Arm(s): Education
D: Arm Label: CBT-I; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I) | Arm Label: CBT-P; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for Pain (CBT-P) | Arm Label: Waitlist Control (WLC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Insomnia (CBT-I); Assigned to Arm(s): CBT-I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Pain (CBT-P); Assigned to Arm(s): CBT-P

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination With Verteporfin (Visudyne(R)) Photodynamic Therapy in Subjects With Neovascular Age Related Macular Degeneration
Brief Summary: The primary purpose of this study is to determine if injections of rhuFab V2 into the eye in combination with verteporfin photodynamic therapy (PDT) is a safe and efficacious treatment for patients with age-related macular degeneration.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination With Verteporfin (Visudyne(R)) Photodynamic Therapy in Subjects With Neovascular Age Related Macular Degeneration
Brief Summary: The primary purpose of this study is to determine if injections of rhuFab V2 into the eye in combination with verteporfin photodynamic therapy (PDT) is a safe and efficacious treatment for patients with age-related macular degeneration.


Options:
A: Arm Label: Aflibercept Blood Sample Collection; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Sample Collection, Drug: Aflibercept | Arm Label: Bevacizumab Blood Sample Collection; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Sample Collection, Drug: Bevacizumab | Arm Label: Ranibizumab Blood Sample Collection; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Sample Collection, Drug: Ranibizumab | Intervention Type: BIOLOGICAL; Name: Blood Sample Collection; Assigned to Arm(s): Aflibercept Blood Sample Collection, Bevacizumab Blood Sample Collection, Ranibizumab Blood Sample Collection | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): Aflibercept Blood Sample Collection | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab Blood Sample Collection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab Blood Sample Collection
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination With Verteporfin (Visudyne(R)) Photodynamic Therapy in Subjects With Neovascular Age Related Macular Degeneration
Brief Summary: The primary purpose of this study is to determine if injections of rhuFab V2 into the eye in combination with verteporfin photodynamic therapy (PDT) is a safe and efficacious treatment for patients with age-related macular degeneration.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): B
C: Arm Label: Bevacizumab 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab 1 | Arm Label: Bevacizumab 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab 1; Assigned to Arm(s): Bevacizumab 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab 2
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.


Options:
A: Arm Label: ACU-4429 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: ACU-4429 5 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: ACU-4429 10 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACU-4429; Assigned to Arm(s): ACU-4429 10 mg, ACU-4429 2.5 mg, ACU-4429 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.


Options:
A: Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: D